Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial.

June 01, 2021 By:
  • de Guillebon E
  • Jimenez M
  • Mazzarella L
  • Betsou F
  • Stadler P
  • Petak I
  • Jeannot E
  • Chanas L
  • Servant N
  • Marret G
  • Duso BA
  • Legrand F
  • Kornerup KN
  • Bernhart SH
  • Balogh G
  • Doczi R
  • Filotas P
  • Curigliano G
  • Bieche I
  • Guerin J
  • Dirner A
  • Neuzillet C
  • Girard N
  • Borcoman E
  • Larbi Cherif L
  • Tresca P
  • Roufai DB
  • Dupain C
  • Scholl S
  • Andre F
  • Fernandez X
  • Filleron T
  • Kamal M
  • Le Tourneau C.

Squamous cell carcinomas (SCCs) are among the most frequent solid tumors in humans. SCCs, related or not to the human papillomavirus, share common molecular features. Immunotherapies, and specifically immune checkpoint inhibitors, have been shown to improve overall survival in multiple cancer types, including SCCs. However, only a minority of patients experience a durable response with immunotherapy. Epigenetic modulation plays a major role in escaping tumor immunosurveillance and confers resistance to immune checkpoint inhibitors. Preclinical evidence suggests that modulating the epigenome might improve the efficacy of immunotherapy. We herein review the preclinical and the clinical rationale for combining immunotherapy with an epidrug, and detail the design of PEVOsq, a basket clinical trial combining pembrolizumab with vorinostat, a histone deacetylase inhibitor, in patients with SCCs of different locations. Sequential blood and tumor sampling will be collected in order to identify predictive and pharmacodynamics biomarkers of efficacy of the combination. We also present how clinical and biological data will be managed with the aim to enable the development of a prospective integrative platform to allow secure and controlled access to the project data as well as further exploitations.

2021 Jun. ESMO Open.6(3):100106. Epub 2021 Apr 14.
Other information